Ophthalmology Drugs Market - Global Forecast to 2030
商品番号 : SMB-80919
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年6月 |
| ページ数 | 329 |
| 図表数 | 425 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
本調査レポートは、眼科薬市場を分子（アフリベルセプト、ファリシマブ、ラニビズマブ、その他）、モダリティ（モノクローナル抗体、融合タンパク質、低分子、その他）、適応症（加齢黄斑変性、糖尿病黄斑浮腫、糖尿病網膜症、その他）、投与経路（硝子体内投与、局所投与、その他）、エンドユーザー（病院、長期ケア施設、専門センター）、地域（北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ）別に分類しています。
本レポートは、眼科薬市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーの詳細な分析により、事業概要、製品、ソリューション、主要戦略、提携、パートナーシップ、契約に関する洞察を提供しています。また、眼科薬市場に関連する新規承認／発売、提携、買収、最近の動向についても取り上げています。
The ophthalmology drugs market is expected to grow from USD 19.52 billion in 2025 to USD 26.28 billion by 2030, registering a CAGR of 6.1% during the forecast period. The growth of the ophthalmology drugs market has primarily been driven by the increasing prevalence of age-related eye diseases and the availability of several key therapies that address these conditions. Additionally, a robust pipeline of new drugs across various treatment modalities contributes to this growth. Opportunities for geographic expansion in emerging economies, such as Asia Pacific, Latin America, the Middle East, and Africa, also support the market’s development.
眼科医薬品市場は、2025年の195.2億米ドルから2030年には262.8億米ドルに成長し、予測期間中に6.1%の年平均成長率（CAGR）を記録すると予測されています。眼科医薬品市場の成長は、主に加齢性眼疾患の罹患率の増加と、これらの疾患に対処する複数の主要治療法の利用可能性によって牽引されています。さらに、様々な治療法にわたる新薬の強力なパイプラインも、この成長に貢献しています。アジア太平洋、ラテンアメリカ、中東、アフリカなどの新興経済国における地理的拡大の機会も、市場の発展を支えています。
The monoclonal antibodies & fusion proteins segment is expected to grow at the highest CAGR during the study period.
Monoclonal antibodies (mAbs) & fusion proteins are anticipated to experience the highest growth rate due to unmet needs in treating retinal diseases, advancements in drug delivery, and recent product approvals. The introduction of biosimilars and upcoming products, such as KSI-301, is expected to enhance competition and reduce costs. Key players in this market, including Regeneron and Roche, are vital for growth, while factors like payor acceptance and technological innovations significantly influence market dynamics.
In addition, emerging markets are increasingly adopting these treatments, benefiting from better access and more affordable pricing, particularly with biosimilars. Less frequent dosing further enhances the cost-effectiveness of these therapies. Innovations such as sustained-release implants and gene therapies are also contributing to growth in this sector. Overall, biosimilars are expanding supply and increasing treatment volume.
The US is expected to grow at the highest CAGR in the global ophthalmology drugs market from 2025 to 2030.
The US is expected to experience the highest CAGR in the global ophthalmology drugs market between 2025 and 2035. This rapid growth is primarily driven by an aging population and the high prevalence of age-related macular degeneration (AMD) and diabetic macular edema (DME). Additionally, there are significant unmet medical needs, recent drug approvals like Syfovre and Izervay, and a promising pipeline for gene and cell therapies. The US also benefits from a strong research and development ecosystem, efficient FDA approval processes, and robust investment. Furthermore, a favorable reimbursement environment, Medicare coverage, and a willingness to adopt expensive therapies contribute significantly to this growth.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (70%) and Demand Side (30%)
- By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%)
- By Region: North America (40%), Europe (25%), the Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)
List of Key Companies Profiled in the Report:
Hoffmann-La Roche Ltd. (Switzerland), Regeneron, Pharmaceuticals Inc. (US), Bayer AG (Germany), AbbVie (US), Novartis AG (Switzerland), Bausch + Lomb (US), Apellis Pharmaceuticals (US), Biogen (US), Astellas Pharma Inc. (US), and Formycon AG (Germany), among others.
Research Coverage:
This research report categorizes the ophthalmology drugs market by molecule (aflibercept, faricimab, ranibizumab, and other molecules), modality (monoclonal antibodies & fusion proteins, small molecules, and other modalities), indication (age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and other indications), route of administration (intravitreal, topical, and other routes of administration), end user (hospitals, long-term care facilities, and specialty centers) and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).
The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the ophthalmology drugs market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the ophthalmology drugs market.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the ophthalmology drugs market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (aging population and growing prevalence of vision disorders, strong drug pipeline and growing innovation efforts, increasing investments and strategic collaborations, and improved reimbursement policies), restraints (off-label drug use for various indications), opportunities (shifting focus on new drug modalities, expansion into emerging markets, and high unmet needs), and challenges (frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment).
- Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the ophthalmology drugs market.
- Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ophthalmology drugs market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the ophthalmology drugs market.
Table of Contents
1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.3 STUDY SCOPE 32
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 32
1.3.2 INCLUSIONS & EXCLUSIONS 33
1.3.3 YEARS CONSIDERED 34
1.3.4 CURRENCY CONSIDERED 34
1.4 STAKEHOLDERS 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH DATA 35
2.1.1 SECONDARY DATA 36
2.1.1.1 Objectives of secondary research 36
2.1.1.2 Key data from secondary sources 37
2.1.2 PRIMARY DATA 37
2.1.2.1 Breakdown of primaries (supply- and demand-side participants) 38
2.1.2.2 Key objectives of primary research 38
2.2 MARKET ESTIMATION METHODOLOGY 39
2.2.1 GLOBAL MARKET ESTIMATION 39
2.2.1.1 Product revenue analysis (bottom-up approach) 39
2.2.1.2 Revenue share analysis of Regeneron Pharmaceuticals, Inc. 40
2.2.1.3 MnM repository analysis 41
2.2.1.4 Primary interviews 41
2.2.2 INSIGHTS OF PRIMARY EXPERTS 41
2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (BOTTOM-UP APPROACH) 42
2.3 MARKET GROWTH RATE PROJECTIONS 43
2.4 DATA TRIANGULATION 45
2.5 STUDY ASSUMPTIONS 45
2.6 RESEARCH LIMITATIONS 46
2.7 RISK ANALYSIS 46
3 EXECUTIVE SUMMARY 47
4 PREMIUM INSIGHTS 51
4.1 OPHTHALMOLOGY DRUGS MARKET OVERVIEW 51
4.2 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE 52
4.3 OPHTHALMOLOGY DRUGS MARKET SHARE, BY END USER, 2024 52
4.4 OPHTHALMOLOGY DRUGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53
5 MARKET OVERVIEW 54
5.1 INTRODUCTION 54
5.2 MARKET DYNAMICS 54
5.2.1 DRIVERS 55
5.2.1.1 Aging population and growing prevalence of vision disorders 55
5.2.1.2 Strong drug pipeline and growing innovation efforts 56
5.2.1.3 Increasing investments and strategic collaborations 57
5.2.1.4 Improved reimbursement policies 57
5.2.2 RESTRAINTS 58
5.2.2.1 Off-label drug use for various indications 58
5.2.3 OPPORTUNITIES 59
5.2.3.1 Shifting focus on new drug modalities 59
5.2.3.2 Expansion into emerging markets 60
5.2.3.3 High unmet needs 61
5.2.4 CHALLENGES 61
5.2.4.1 Frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment 61
5.3 TECHNOLOGY ANALYSIS 62
5.3.1 KEY TECHNOLOGIES 63
5.3.1.1 Hybridoma technology 63
5.3.1.2 Recombinant DNA technology 63
5.3.1.3 Antibody engineering 64
5.3.1.4 Gene therapy 64
5.3.1.5 Nanoformulations 65
5.3.2 ADJACENT TECHNOLOGIES 65
5.3.2.1 Optogenetic technology 65
5.3.2.2 Drug-release technologies 66
5.3.2.3 Ocular implant technologies 66
5.3.3 COMPLEMENTARY TECHNOLOGIES 66
5.3.3.1 3D printing and bioprinting 66
5.3.3.2 Ocular imaging technologies 67
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67
5.5 PRICING ANALYSIS 67
5.5.1 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024 68
5.5.2 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024 68
5.5.3 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024 69
5.6 VALUE CHAIN ANALYSIS 69
5.7 ECOSYSTEM ANALYSIS 71
5.7.1 OPHTHALMOLOGY DRUGS MARKET: ROLE OF RAW MATERIAL SUPPLIERS 72
5.7.2 OPHTHALMOLOGY DRUGS MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES 73
5.7.3 OPHTHALMOLOGY DRUGS MARKET: ROLE OF END USERS 74
5.7.4 OPHTHALMOLOGY DRUGS MARKET: ROLE OF REGULATORY AUTHORITIES 74
5.8 PATENT ANALYSIS 75
5.9 REGULATORY ANALYSIS 76
5.9.1 REGULATORY LANDSCAPE 76
5.9.1.1 US 77
5.9.1.2 Europe 78
5.9.1.3 Emerging markets 78
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 79
5.10 PORTER’S FIVE FORCES ANALYSIS 82
5.10.1 INTENSITY OF COMPETITIVE RIVALRY 84
5.10.2 BARGAINING POWER OF SUPPLIERS 84
5.10.3 BARGAINING POWER OF BUYERS 84
5.10.4 THREAT OF SUBSTITUTES 84
5.10.5 THREAT OF NEW ENTRANTS 85
5.11 KEY CONFERENCES & EVENTS, 2025–2026 85
5.12 REIMBURSEMENT SCENARIO 86
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 86
5.13.1 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS 87
5.14 INVESTMENT & FUNDING SCENARIO 88
5.15 PIPELINE ANALYSIS 89
5.16 IMPACT OF ARTIFICIAL INTELLIGENCE ON OPHTHALMOLOGY DRUGS MARKET 92
5.16.1 CHALLENGES IN DRUG DISCOVERY 93
5.16.2 IMPACT OF AI ON DISCOVERY OF OPHTHALMOLOGY DRUGS 93
5.17 IMPACT OF 2025 US TARIFFS ON OPHTHALMOLOGY DRUGS MARKET 94
5.17.1 KEY TARIFF RATES 94
5.17.2 PRICE IMPACT ANALYSIS 95
5.17.3 KEY IMPACT ON VARIOUS REGIONS 96
5.17.3.1 US 96
5.17.3.2 Europe 96
5.17.3.3 APAC 96
5.17.4 MANUFACTURING INDUSTRY IMPACT 97
5.17.4.1 Ophthalmology drug manufacturers 97
6 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE 98
6.1 INTRODUCTION 99
6.2 AFLIBERCEPT 99
6.2.1 HIGH EFFICIENCY OF AFLIBERCEPT IN TREATING RETINAL DISEASES TO DRIVE MARKET GROWTH 99
6.3 FARICIMAB 102
6.3.1 GROWING ADOPTION AND POSITIVE OUTCOMES OF STUDIES TO SUPPORT MARKET GROWTH 102
6.4 RANIBIZUMAB 105
6.4.1 CLINICAL EFFICACY OF RANIBIZUMAB TO DRIVE ADOPTION 105
6.5 OTHER MOLECULES 108
7 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY 112
7.1 INTRODUCTION 113
7.2 MONOCLONAL ANTIBODIES & FUSION PROTEINS 113
7.2.1 GROWING FOCUS ON DEVELOPING NEW MABS TO DRIVE MARKET 113
7.3 SMALL MOLECULES 116
7.3.1 INCREASING INVESTMENTS AND RESEARCH TO DRIVE MARKET 116
7.4 OTHER MODALITIES 119
8 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION 123
8.1 INTRODUCTION 124
8.2 AGE-RELATED MACULAR DEGENERATION 124
8.2.1 WET AGE-RELATED MACULAR DEGENERATION 127
8.2.1.1 Increasing demand for effective therapies to drive market 127
8.2.2 DRY AGE-RELATED MACULAR DEGENERATION 130
8.2.2.1 Large market opportunity for innovation to drive growth 130
8.3 DIABETIC RETINOPATHY (DR) 131
8.3.1 FEWER APPROVED DRUGS TO PRESENT MARKET OPPORTUNITIES 131
8.4 DIABETIC MACULAR EDEMA (DME) 133
8.4.1 GROWING ADOPTION OF APPROVED ANTI-VEGF DRUGS FOR DME
TO DRIVE MARKET 133
8.5 OTHER INDICATIONS 136
9 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION 139
9.1 INTRODUCTION 140
9.2 INTRAVITREAL 140
9.2.1 HIGH EFFICACY OF INTRAVITREAL INJECTIONS IN TREATMENT OF MAJOR RETINAL DISEASES TO DRIVE MARKET 140
9.3 TOPICAL 143
9.3.1 EASE OF USE TO DRIVE DEMAND FOR TOPICAL DRUGS 143
9.4 OTHER ROUTES OF ADMINISTRATION 145
10 OPHTHALMOLOGY DRUGS MARKET, BY END USER 148
10.1 INTRODUCTION 149
10.2 HOSPITALS 149
10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO ENCOURAGE GROWTH 149
10.3 LONG-TERM CARE FACILITIES 152
10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET 152
10.4 SPECIALTY CENTERS 154
10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS
TO ACCELERATE GROWTH 154
11 OPHTHALMOLOGY DRUGS MARKET, BY REGION 158
11.1 INTRODUCTION 159
11.2 NORTH AMERICA 159
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 160
11.2.2 US 164
11.2.2.1 Rising investments in healthcare research and development
to support growth 164
11.2.3 CANADA 167
11.2.3.1 Rising government initiatives to support ophthalmology drugs research and increasing drug approvals to support growth 167
11.3 EUROPE 170
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 170
11.3.2 GERMANY 175
11.3.2.1 Rising focus on clinical research to drive market 175
11.3.3 UK 178
11.3.3.1 Ongoing advancements in technology to drive market growth 178
11.3.4 FRANCE 181
11.3.4.1 Growing investments and government support to drive market growth 181
11.3.5 ITALY 183
11.3.5.1 Growing investments and research to support market 183
11.3.6 SPAIN 186
11.3.6.1 Growing geriatric population to drive market growth 186
11.3.7 REST OF EUROPE 189
11.4 ASIA PACIFIC 191
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 191
11.4.2 CHINA 195
11.4.2.1 Large diabetic population to boost market 195
11.4.3 JAPAN 198
11.4.3.1 Growing aging population to intensify demand for effective treatments 198
11.4.4 INDIA 201
11.4.4.1 Increasing diabetic cases, government support, and growing availability of biosimilars to support market 201
11.4.5 AUSTRALIA 203
11.4.5.1 Strong biopharmaceutical sector to drive market growth 203
11.4.6 SOUTH KOREA 206
11.4.6.1 Strong R&D pipeline and increasing focus on research to support growth 206
11.4.7 REST OF ASIA PACIFIC 209
11.5 LATIN AMERICA 211
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 211
11.5.2 BRAZIL 215
11.5.2.1 Significant rates of visual impairment in region to drive demand
for advanced treatments 215
11.5.3 MEXICO 218
11.5.3.1 Growing research initiatives and innovations to support
market growth 218
11.5.4 REST OF LATIN AMERICA 221
11.6 MIDDLE EAST 224
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 224
11.6.2 GCC COUNTRIES 227
11.6.2.1 Growing research initiatives and improving healthcare infrastructure to support growth 227
11.6.3 REST OF MIDDLE EAST 230
11.7 AFRICA 233
11.7.1 GROWING FOCUS ON HEALTHCARE TO DRIVE MARKET GROWTH 233
11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 233
12 COMPETITIVE LANDSCAPE 237
12.1 INTRODUCTION 237
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 237
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET 237
12.3 REVENUE ANALYSIS, 2022–2024 238
12.4 MARKET SHARE ANALYSIS, 2024 239
12.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2024 242
12.5.1 STARS 242
12.5.2 EMERGING LEADERS 242
12.5.3 PERVASIVE PLAYERS 242
12.5.4 PARTICIPANTS 242
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 244
12.5.5.1 Company footprint 244
12.5.5.2 Region footprint 245
12.5.5.3 Molecule footprint 246
12.5.5.4 Modality footprint 247
12.5.5.5 Indication footprint 248
12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024 249
12.6.1 PROGRESSIVE COMPANIES 249
12.6.2 RESPONSIVE COMPANIES 249
12.6.3 DYNAMIC COMPANIES 249
12.6.4 STARTING BLOCKS 249
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 251
12.6.5.1 Detailed list of key startups/SMEs 251
12.6.5.2 Competitive benchmarking of startups/SMEs 252
12.7 COMPANY VALUATION & FINANCIAL METRICS 253
12.7.1 VALUATION OF KEY PLAYERS 253
12.7.2 FINANCIAL METRICS OF KEY PLAYERS 253
12.8 BRAND/PRODUCT COMPARISON 254
12.9 COMPETITIVE SCENARIO 255
12.9.1 PRODUCT LAUNCHES & APPROVALS 255
12.9.2 DEALS 256
13 COMPANY PROFILES 257
13.1 KEY PLAYERS 257
13.1.1 REGENERON PHARMACEUTICALS INC. 257
13.1.1.1 Business overview 257
13.1.1.2 Products offered 258
13.1.1.3 Recent developments 259
13.1.1.3.1 Product approvals 259
13.1.1.4 MnM view 259
13.1.1.4.1 Right to win 259
13.1.1.4.2 Strategic choices 259
13.1.1.4.3 Weaknesses & competitive threats 260
13.1.2 F. HOFFMANN-LA ROCHE LTD. 261
13.1.2.1 Business overview 261
13.1.2.2 Products offered 262
13.1.2.3 Recent developments 263
13.1.2.3.1 Product launches & approvals 263
13.1.2.4 MnM view 264
13.1.2.4.1 Right to win 264
13.1.2.4.2 Strategic choices 264
13.1.2.4.3 Weaknesses & competitive threats 265
13.1.3 BAYER AG 266
13.1.3.1 Business overview 266
13.1.3.2 Products offered 267
13.1.3.3 Recent developments 268
13.1.3.3.1 Product approvals 268
13.1.3.4 MnM view 268
13.1.3.4.1 Right to win 268
13.1.3.4.2 Strategic choices 269
13.1.3.4.3 Weaknesses & competitive threats 269
13.1.4 NOVARTIS AG 270
13.1.4.1 Business overview 270
13.1.4.2 Products offered 271
13.1.4.3 Recent developments 272
13.1.4.3.1 Product approvals 272
13.1.4.3.2 Deals 272
13.1.4.4 MnM view 273
13.1.4.4.1 Right to win 273
13.1.4.4.2 Strategic choices 273
13.1.4.4.3 Weaknesses & competitive threats 273
13.1.5 ABBVIE 274
13.1.5.1 Business overview 274
13.1.5.2 Products offered 275
13.1.6 APELLIS PHARMACEUTICALS 276
13.1.6.1 Business overview 276
13.1.6.2 Products offered 277
13.1.6.3 Recent developments 278
13.1.6.3.1 Product approvals 278
13.1.6.3.2 Deals 278
13.1.7 BIOGEN 279
13.1.7.1 Business overview 279
13.1.7.2 Products offered 280
13.1.7.3 Recent developments 281
13.1.7.3.1 Product launches & approvals 281
13.1.8 BAUSCH + LOMB 283
13.1.8.1 Business overview 283
13.1.8.2 Products offered 285
13.1.8.3 Recent developments 287
13.1.8.3.1 Product launches & approvals 287
13.1.9 ASTELLAS PHARMA INC. 288
13.1.9.1 Business overview 288
13.1.9.2 Products offered 289
13.1.9.3 Recent developments 290
13.1.9.3.1 Product approvals 290
13.1.9.3.2 Deals 290
13.1.10 FORMYCON AG 291
13.1.10.1 Business overview 291
13.1.10.2 Products offered 292
13.1.10.3 Recent developments 293
13.1.10.3.1 Product launches & approvals 293
13.1.10.3.2 Deals 294
13.1.11 BIOCON 295
13.1.11.1 Business overview 295
13.1.11.2 Products offered 296
13.1.11.3 Recent developments 296
13.1.11.3.1 Product approvals 296
13.1.11.3.2 Deals 296
13.1.12 SANDOZ GROUP AG 297
13.1.12.1 Business overview 297
13.1.12.2 Products offered 298
13.1.12.3 Recent developments 299
13.1.12.3.1 Product approvals 299
13.1.12.3.2 Deals 299
13.1.13 SANTEN PHARMACEUTICAL CO., LTD. 300
13.1.13.1 Business overview 300
13.1.13.2 Products offered 301
13.1.13.3 Recent developments 302
13.1.13.3.1 Product launches 302
13.1.14 INNOVENT 303
13.1.14.1 Business overview 303
13.1.14.2 Products offered 304
13.1.14.3 Recent developments 304
13.1.14.3.1 Product approvals 304
13.1.15 OUTLOOK THERAPEUTICS, INC. 305
13.1.15.1 Business overview 305
13.1.15.2 Products offered 305
13.1.15.3 Recent developments 306
13.1.15.3.1 Product approvals 306
13.1.15.3.2 Deals 306
13.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD. 307
13.1.16.1 Business overview 307
13.1.16.2 Products offered 308
13.1.16.3 Recent developments 309
13.1.16.3.1 Product approvals 309
13.1.16.3.2 Deals 310
13.2 OTHER PLAYERS (PIPELINE COMPANIES) 311
13.2.1 OCULAR THERAPEUTIX, INC. 311
13.2.2 OPTHEA LIMITED 312
13.2.3 KODIAK SCIENCES INC. 313
13.2.4 EYEPOINT PHARMACEUTICALS, INC. 314
13.2.5 ALVOTECH 315
13.2.6 CLEARSIDE BIOMEDICAL 316
13.2.7 SHANGHAI HENLIUS BIOTECH, INC. 317
13.2.8 ADVERUM BIOTECHNOLOGIES, INC. 318
13.2.9 REMEGEN 319
13.2.10 SPARINGVISION 320
14 APPENDIX 321
14.1 DISCUSSION GUIDE 321
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 325
14.3 CUSTOMIZATION OPTIONS 327
14.4 RELATED REPORTS 327
14.5 AUTHOR DETAILS 328
LIST OF TABLES
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 44
TABLE 2 OPHTHALMOLOGY DRUGS MARKET: RISK ANALYSIS 46
TABLE 3 OPHTHALMOLOGY DRUGS MARKET: IMPACT ANALYSIS 55
TABLE 4 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024 68
TABLE 5 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024 69
TABLE 6 OPHTHALMOLOGY DRUGS MARKET: LIST OF RAW MATERIAL SUPPLIERS 72
TABLE 7 OPHTHALMOLOGY DRUGS MARKET: LIST OF PRODUCT PROVIDERS AND
PHASE III PIPELINE PRODUCT COMPANIES 73
TABLE 8 OPHTHALMOLOGY DRUGS MARKET: LIST OF END USERS 74
TABLE 9 OPHTHALMOLOGY DRUGS MARKET: LIST OF REGULATORY AUTHORITIES 74
TABLE 10 OPHTHALMOLOGY DRUGS MARKET: INDICATIVE LIST OF PATENTS, 2024 75
TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 79
TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 80
TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 81
TABLE 14 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 82
TABLE 15 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT
AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 16 OPHTHALMOLOGY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS 83
TABLE 17 OPHTHALMOLOGY DRUGS MARKET: LIST OF CONFERENCES & EVENTS 85
TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%) 87
TABLE 19 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS, BY END USER 87
TABLE 20 OPHTHALMOLOGY DRUGS IN CLINICAL PIPELINE, PHASE III (AS OF APRIL 2025) 90
TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES 94
TABLE 22 EXPORTS AND IMPORTS, BY REGION 95
TABLE 23 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 99
TABLE 24 OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY REGION,
2023–2030 (USD MILLION) 100
TABLE 25 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT,
BY COUNTRY, 2023–2030 (USD MILLION) 100
TABLE 26 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION) 101
TABLE 27 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION) 101
TABLE 28 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT,
BY COUNTRY, 2023–2030 (USD MILLION) 102
TABLE 29 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT,
BY REGION, 2023–2030 (USD MILLION) 102
TABLE 30 OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION,
2023–2030 (USD MILLION) 103
TABLE 31 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB,
BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 32 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 33 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 34 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB,
BY COUNTRY, 2023–2030 (USD MILLION) 105
TABLE 35 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION, 2023–2030 (USD MILLION) 105
TABLE 36 OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION,
2023–2030 (USD MILLION) 106
TABLE 37 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB,
BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 38 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 39 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB,
BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 40 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB,
BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 41 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2023–2030 (USD MILLION) 108
TABLE 42 OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY REGION,
2023–2030 (USD MILLION) 109
TABLE 43 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES,
BY COUNTRY, 2023–2030 (USD MILLION) 109
TABLE 44 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES,
BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 45 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES,
BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 46 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES,
BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 47 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES,
BY REGION, 2023–2030 (USD MILLION) 111
TABLE 48 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 113
TABLE 49 OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023–2030 (USD MILLION) 114
TABLE 50 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 51 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES
& FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 52 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 53 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 54 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023–2030 (USD MILLION) 115
TABLE 55 OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY REGION,
2023–2030 (USD MILLION) 117
TABLE 56 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2023–2030 (USD MILLION) 117
TABLE 57 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 58 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 59 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES,
BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 60 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES,
BY REGION, 2023–2030 (USD MILLION) 119
TABLE 61 OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY REGION,
2023–2030 (USD MILLION) 120
TABLE 62 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES,
BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 63 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES,
BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 64 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES,
BY COUNTRY, 2023–2030 (USD MILLION) 121
TABLE 65 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES,
BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 66 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES,
BY REGION, 2023–2030 (USD MILLION) 122
TABLE 67 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 124
TABLE 68 OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 125
TABLE 69 OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION) 125
TABLE 70 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 71 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 72 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 73 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 74 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION) 127
TABLE 75 OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION) 128
TABLE 76 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 128
TABLE 77 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 78 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 129
TABLE 79 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 80 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION) 130
TABLE 81 OPHTHALMOLOGY DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION) 131
TABLE 82 OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY,
BY REGION, 2023–2030 (USD MILLION) 132
TABLE 83 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 84 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY,
BY COUNTRY, 2023–2030 (USD MILLION) 133
TABLE 85 OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023–2030 (USD MILLION) 134
TABLE 86 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 87 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA,
BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 88 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 89 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 90 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023–2030 (USD MILLION) 135
TABLE 91 OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY REGION,
2023–2030 (USD MILLION) 136
TABLE 92 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 93 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 94 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 95 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 96 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS,
BY REGION, 2023–2030 (USD MILLION) 138
TABLE 97 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 140
TABLE 98 OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION) 141
TABLE 99 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL
ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 100 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 101 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 102 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE
OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 103 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION) 142
TABLE 104 OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION,
BY REGION, 2023–2030 (USD MILLION) 143
TABLE 105 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 106 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 107 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE
OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 144
TABLE 108 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 145
TABLE 109 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE
OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION) 145
TABLE 110 OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION,
BY REGION, 2023–2030 (USD MILLION) 146
TABLE 111 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 112 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 113 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES
OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 114 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 115 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES
OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION) 147
TABLE 116 OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION) 149
TABLE 117 OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION,
2023–2030 (USD MILLION) 150
TABLE 118 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS,
BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 119 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 120 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 121 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS,
BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 122 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION) 151
TABLE 123 OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION) 152
TABLE 124 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 125 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 126 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 127 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 128 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION) 154
TABLE 129 OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION,
2023–2030 (USD MILLION) 155
TABLE 130 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 131 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS,
BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 132 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS,
BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 133 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS,
BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 134 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS,
BY REGION, 2023–2030 (USD MILLION) 157
TABLE 135 OPHTHALMOLOGY DRUGS MARKET, BY REGION, 2023–2030 (USD MILLION) 159
TABLE 136 NORTH AMERICA: MACROECONOMIC INDICATORS 160
TABLE 137 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 162
TABLE 138 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 162
TABLE 139 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 162
TABLE 140 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 163
TABLE 141 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 163
TABLE 142 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 163
TABLE 143 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 164
TABLE 144 US: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 165
TABLE 145 US: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 165
TABLE 146 US: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 166
TABLE 147 US: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 166
TABLE 148 US: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 166
TABLE 149 US: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 167
TABLE 150 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 168
TABLE 151 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 168
TABLE 152 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 168
TABLE 153 CANADA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 169
TABLE 154 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 169
TABLE 155 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 169
TABLE 156 EUROPE: MACROECONOMIC INDICATORS 171
TABLE 157 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 173
TABLE 158 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 173
TABLE 159 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 173
TABLE 160 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 174
TABLE 161 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 174
TABLE 162 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 174
TABLE 163 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 175
TABLE 164 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 176
TABLE 165 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 176
TABLE 166 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 177
TABLE 167 GERMANY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 177
TABLE 168 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 177
TABLE 169 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 178
TABLE 170 UK: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 179
TABLE 171 UK: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 179
TABLE 172 UK: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 179
TABLE 173 UK: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 180
TABLE 174 UK: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 180
TABLE 175 UK: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 180
TABLE 176 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 181
TABLE 177 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 182
TABLE 178 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 182
TABLE 179 FRANCE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 182
TABLE 180 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 183
TABLE 181 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 183
TABLE 182 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 184
TABLE 183 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 184
TABLE 184 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 185
TABLE 185 ITALY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 185
TABLE 186 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 185
TABLE 187 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 186
TABLE 188 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 187
TABLE 189 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 187
TABLE 190 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 187
TABLE 191 SPAIN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 188
TABLE 192 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 188
TABLE 193 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 188
TABLE 194 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 189
TABLE 195 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 190
TABLE 196 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 190
TABLE 197 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 190
TABLE 198 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 191
TABLE 199 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 191
TABLE 200 ASIA PACIFIC: MACROECONOMIC INDICATORS 193
TABLE 201 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 193
TABLE 202 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 193
TABLE 203 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 194
TABLE 204 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 194
TABLE 205 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 194
TABLE 206 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 195
TABLE 207 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 195
TABLE 208 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 196
TABLE 209 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 196
TABLE 210 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 197
TABLE 211 CHINA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 197
TABLE 212 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 197
TABLE 213 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 198
TABLE 214 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 199
TABLE 215 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 199
TABLE 216 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 199
TABLE 217 JAPAN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 200
TABLE 218 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 200
TABLE 219 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 200
TABLE 220 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 201
TABLE 221 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 202
TABLE 222 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 202
TABLE 223 INDIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 202
TABLE 224 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION,
2023–2030 (USD MILLION) 203
TABLE 225 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 203
TABLE 226 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 204
TABLE 227 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 204
TABLE 228 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 205
TABLE 229 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 205
TABLE 230 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 205
TABLE 231 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 206
TABLE 232 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 207
TABLE 233 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 207
TABLE 234 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 207
TABLE 235 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED
MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 208
TABLE 236 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 208
TABLE 237 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 208
TABLE 238 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 209
TABLE 239 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 210
TABLE 240 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 210
TABLE 241 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 210
TABLE 242 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 211
TABLE 243 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 211
TABLE 244 LATIN AMERICA: MACROECONOMIC INDICATORS 212
TABLE 245 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 213
TABLE 246 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 213
TABLE 247 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 213
TABLE 248 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 214
TABLE 249 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED
MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 214
TABLE 250 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 214
TABLE 251 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 215
TABLE 252 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 216
TABLE 253 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 216
TABLE 254 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 217
TABLE 255 BRAZIL: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 217
TABLE 256 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 217
TABLE 257 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 218
TABLE 258 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 219
TABLE 259 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 219
TABLE 260 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 220
TABLE 261 MEXICO: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 220
TABLE 262 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 220
TABLE 263 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 221
TABLE 264 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION) 222
TABLE 265 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION) 222
TABLE 266 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 223
TABLE 267 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 223
TABLE 268 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 223
TABLE 269 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET,
BY END USER, 2023–2030 (USD MILLION) 224
TABLE 270 MIDDLE EAST: MACROECONOMIC INDICATORS 225
TABLE 271 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 225
TABLE 272 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 226
TABLE 273 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 226
TABLE 274 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED
MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 226
TABLE 275 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 227
TABLE 276 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 227
TABLE 277 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 228
TABLE 278 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 228
TABLE 279 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 228
TABLE 280 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED
MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 229
TABLE 281 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 229
TABLE 282 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 229
TABLE 283 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 230
TABLE 284 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 231
TABLE 285 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION) 231
TABLE 286 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 232
TABLE 287 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE
OF ADMINISTRATION, 2023–2030 (USD MILLION) 232
TABLE 288 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 232
TABLE 289 AFRICA: MACROECONOMIC INDICATORS 234
TABLE 290 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE,
2023–2030 (USD MILLION) 234
TABLE 291 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY,
2023–2030 (USD MILLION) 234
TABLE 292 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2023–2030 (USD MILLION) 235
TABLE 293 AFRICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION) 235
TABLE 294 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION) 235
TABLE 295 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER,
2023–2030 (USD MILLION) 236
TABLE 296 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS
IN OPHTHALMOLOGY DRUGS MARKET 237
TABLE 297 OPHTHALMOLOGY DRUGS MARKET: DEGREE OF COMPETITION 240
TABLE 298 OPHTHALMOLOGY DRUGS MARKET: REGION FOOTPRINT 245
TABLE 299 OPHTHALMOLOGY DRUGS MARKET: MOLECULE FOOTPRINT 246
TABLE 300 OPHTHALMOLOGY DRUGS MARKET: MODALITY FOOTPRINT 247
TABLE 301 OPHTHALMOLOGY DRUGS MARKET: INDICATION FOOTPRINT 248
TABLE 302 OPHTHALMOLOGY DRUGS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 251
TABLE 303 OPHTHALMOLOGY DRUGS MARKET: COMPETITIVE BENCHMARKING
OF START-UP/SME PLAYERS 252
TABLE 304 OPHTHALMOLOGY DRUGS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–MAY 2025 255
TABLE 305 OPHTHALMOLOGY DRUGS MARKET: DEALS, JANUARY 2022–MAY 2025 256
TABLE 306 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW 257
TABLE 307 REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED 258
TABLE 308 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS,
JANUARY 2021–MAY 2025 259
TABLE 309 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 261
TABLE 310 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 262
TABLE 311 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2021–MAY 2025 263
TABLE 312 BAYER AG: COMPANY OVERVIEW 266
TABLE 313 BAYER AG: PRODUCTS OFFERED 267
TABLE 314 BAYER AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 268
TABLE 315 NOVARTIS AG: COMPANY OVERVIEW 270
TABLE 316 NOVARTIS AG: PRODUCTS OFFERED 271
TABLE 317 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 272
TABLE 318 NOVARTIS AG: DEALS, JANUARY 2021–MAY 2025 272
TABLE 319 ABBVIE: COMPANY OVERVIEW 274
TABLE 320 ABBVIE: PRODUCTS OFFERED 275
TABLE 321 APELLIS PHARMACEUTICALS: COMPANY OVERVIEW 276
TABLE 322 APELLIS PHARMACEUTICALS: PRODUCTS OFFERED 277
TABLE 323 APELLIS PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 278
TABLE 324 APELLIS PHARMACEUTICALS: DEALS, JANUARY 2021–MAY 2025 278
TABLE 325 BIOGEN: COMPANY OVERVIEW 279
TABLE 326 BIOGEN: PRODUCTS OFFERED 280
TABLE 327 BIOGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 281
TABLE 328 BAUSCH + LOMB: COMPANY OVERVIEW 283
TABLE 329 BAUSCH + LOMB: PRODUCTS OFFERED 285
TABLE 330 BAUSCH + LOMB: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 287
TABLE 331 ASTELLAS PHARMA INC.: COMPANY OVERVIEW 288
TABLE 332 ASTELLAS PHARMA INC.: PRODUCTS OFFERED 289
TABLE 333 ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 290
TABLE 334 ASTELLAS PHARMA INC.: DEALS, JANUARY 2021–JULY 2024 290
TABLE 335 FORMYCON AG: COMPANY OVERVIEW 291
TABLE 336 FORMYCON AG: PRODUCTS OFFERED 292
TABLE 337 FORMYCON AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 293
TABLE 338 FORMYCON AG: DEALS, JANUARY 2021–MAY 2025 294
TABLE 339 BIOCON: COMPANY OVERVIEW 295
TABLE 340 BIOCON: PRODUCTS OFFERED 296
TABLE 341 BIOCON: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 296
TABLE 342 BIOCON: DEALS, JANUARY 2021–MAY 2025 296
TABLE 343 SANDOZ GROUP AG: COMPANY OVERVIEW 297
TABLE 344 SANDOZ GROUP AG: PRODUCTS OFFERED 298
TABLE 345 SANDOZ GROUP AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 299
TABLE 346 SANDOZ GROUP AG: DEALS, JANUARY 2021–JULY 2024 299
TABLE 347 SANTEN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW 300
TABLE 348 SANTEN PHARMACEUTICALS CO., LTD.: PRODUCTS OFFERED 301
TABLE 349 SANTEN PHARMACEUTICAL CO., LTD: PRODUCT LAUNCHES,
JANUARY 2021–MAY 2025 302
TABLE 350 INNOVENT: COMPANY OVERVIEW 303
TABLE 351 INNOVENT: PRODUCTS OFFERED 304
TABLE 352 INNOVENT: PRODUCT APPROVALS, JANUARY 2021–MAY 2025 304
TABLE 353 OUTLOOK THERAPEUTICS, INC.: COMPANY OVERVIEW 305
TABLE 354 OUTLOOK THERAPEUTICS, INC.: PRODUCTS OFFERED 305
TABLE 355 OUTLOOK THERAPEUTICS, INC.: PRODUCT APPROVALS, JANUARY 2022–MAY 2025 306
TABLE 356 OUTLOOK THERAPEUTICS, INC.: DEALS, JANUARY 2022–MAY 2025 306
TABLE 357 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 307
TABLE 358 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 308
TABLE 359 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS,
JANUARY 2022–MAY 2025 309
TABLE 360 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2022–MAY 2025 310
TABLE 361 OCULAR THERAPEUTIX, INC.: COMPANY OVERVIEW 311
TABLE 362 OPTHEA LIMITED: COMPANY OVERVIEW 312
TABLE 363 KODIAK SCIENCES INC.: COMPANY OVERVIEW 313
TABLE 364 EYEPOINT PHARMACEUTICALS, INC.: COMPANY OVERVIEW 314
TABLE 365 ALVOTECH: COMPANY OVERVIEW 315
TABLE 366 CLEARSIDE BIOMEDICAL: COMPANY OVERVIEW 316
TABLE 367 SHANGHAI HENLIUS BIOTECH, INC.: COMPANY OVERVIEW 317
TABLE 368 ADVERUM BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW 318
TABLE 369 REMEGEN: COMPANY OVERVIEW 319
TABLE 370 SPARINGVISION: COMPANY OVERVIEW 320
LIST OF FIGURES
FIGURE 1 OPHTHALMOLOGY DRUGS MARKET SEGMENTATION & REGIONAL SCOPE 32
FIGURE 2 OPHTHALMOLOGY DRUGS MARKET: RESEARCH DESIGN 35
FIGURE 3 OPHTHALMOLOGY DRUGS MARKET: KEY DATA FROM SECONDARY SOURCES 37
FIGURE 4 OPHTHALMOLOGY DRUGS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 38
FIGURE 5 OPHTHALMOLOGY DRUGS MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2024 39
FIGURE 6 PRODUCT REVENUE ANALYSIS-BASED ESTIMATION:
BOTTOM-UP APPROACH (2024) 40
FIGURE 7 REVENUE SHARE ANALYSIS OF REGENERON PHARMACEUTICALS, INC. (2024) 40
FIGURE 8 OPHTHALMOLOGY DRUGS MARKET SIZE VALIDATION FROM PRIMARY SOURCES 41
FIGURE 9 OPHTHALMOLOGY DRUGS MARKET: BOTTOM-UP APPROACH 42
FIGURE 10 OPHTHALMOLOGY DRUGS MARKET: CAGR PROJECTIONS 43
FIGURE 11 OPHTHALMOLOGY DRUGS MARKET: DATA TRIANGULATION 45
FIGURE 12 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2025 VS. 2030 (USD MILLION) 47
FIGURE 13 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION) 48
FIGURE 14 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION,
2025 VS. 2030 (USD MILLION) 48
FIGURE 15 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,
2025 VS. 2030 (USD MILLION) 49
FIGURE 16 OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 49
FIGURE 17 GEOGRAPHIC ANALYSIS: OPHTHALMOLOGY DRUGS MARKET 50
FIGURE 18 GROWING PREVALENCE OF RETINAL DISEASES AND INCREASING
R&D INVESTMENTS TO DRIVE MARKET GROWTH 51
FIGURE 19 AFLIBERCEPT ACCOUNTED FOR LARGEST SHARE OF OPHTHALMOLOGY
DRUGS MARKET IN NORTH AMERICA IN 2024 52
FIGURE 20 HOSPITALS TO DOMINATE MARKET DURING FORECAST PERIOD 52
FIGURE 21 NORTH AMERICA LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL OPHTHALMOLOGY DRUGS MARKET DURING FORECAST PERIOD 53
FIGURE 22 OPHTHALMOLOGY DRUGS MARKET: DRIVERS, RESTRAINTS,
OPPORTUNITIES, AND CHALLENGES 54
FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 67
FIGURE 24 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024 68
FIGURE 25 OPHTHALMOLOGY DRUGS MARKET: VALUE CHAIN ANALYSIS 70
FIGURE 26 OPHTHALMOLOGY DRUGS MARKET: ECOSYSTEM ANALYSIS 72
FIGURE 27 OPHTHALMOLOGY DRUGS MARKET: PATENT PUBLICATION TRENDS, JURISDICTION, AND TOP APPLICANT ANALYSIS (JANUARY 2014–DECEMBER 2024) 75
FIGURE 28 OPHTHALMOLOGY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS 83
FIGURE 29 KEY STAKEHOLDERS IN BUYING PROCESS OF OPHTHALMOLOGY
DRUGS, BY MODALITY 86
FIGURE 30 KEY BUYING CRITERIA FOR END USERS 87
FIGURE 31 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT 161
FIGURE 32 EUROPE: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT 172
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION) 239
FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024 240
FIGURE 35 OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 243
FIGURE 36 OPHTHALMOLOGY DRUGS MARKET: COMPANY FOOTPRINT 244
FIGURE 37 OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION
MATRIX (STARTUPS/SMES), 2024 250
FIGURE 38 EV/EBITDA OF KEY PLAYERS 253
FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY PLAYERS 253
FIGURE 40 OPHTHALMOLOGY DRUGS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 254
FIGURE 41 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024) 258
FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 262
FIGURE 43 BAYER AG: COMPANY SNAPSHOT (2024) 267
FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT (2024) 271
FIGURE 45 ABBVIE: COMPANY SNAPSHOT (2024) 275
FIGURE 46 APELLIS PHARMACEUTICALS: COMPANY SNAPSHOT (2024) 277
FIGURE 47 BIOGEN: COMPANY SNAPSHOT (2024) 280
FIGURE 48 BAUSCH + LOMB: COMPANY SNAPSHOT (2024) 284
FIGURE 49 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2024) 289
FIGURE 50 FORMYCON AG: COMPANY SNAPSHOT (2024) 292
FIGURE 51 BIOCON: COMPANY SNAPSHOT (2024) 295
FIGURE 52 SANDOZ GROUP AG: COMPANY SNAPSHOT (2024) 298
FIGURE 53 SANTEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT (2024) 301
FIGURE 54 INNOVENT: COMPANY SNAPSHOT (2024) 303
FIGURE 55 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024) 308
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | USD9,150 | USD9,650 | USD11,500 |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 水性バリアコーティング市場 – 2030年までの世界予測 2025-07-03
- 工作機械市場 – 2032年までの世界予測 2025-07-03
- 軟組織修復市場 – 2030年までの世界予測 2025-07-02
- エポキシ樹脂市場 – 2030年までの世界予測 2025-07-02
- スマートガスメーター市場 – 2030年までの世界予測 2025-07-02